Drugs / JNJ-40411813
Trials 10
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2024-04-29 | Addex Pharma S.A. | Results Addex Provides Update on ADX71149 Phase 2 Epilepsy Study addextherapeutics.com ↗
The Phase 2 study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care. |
| 2021-01-21 | Addex Pharma S.A. | Regulatory Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. |
| 2018-10-22 | Addex Pharma S.A. | Results Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy addextherapeutics.com ↗
Phase I studies in several hundred individuals found ADX71149 to be safe and well tolerated. |
| 2018-09-04 | Addex Pharma S.A. | Results Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today publication of a study demonstrating the potential therapeutic effect of ADX71149 (JNJ-40411813), a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), in severe panic disorders and post-traumatic stress disorder (PTSD). |
| 2017-02-27 | Addex Pharma S.A. | Results Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN) announced today the publication of a study demonstrating the anti-epileptic effects of ADX71149, a metabotropic glutamate receptor subtype 2 (mGlu2) positive allosteric modulator (PAM), given alone or in combination with the globally marketed antiseizure drug levetiracetam (LEV) in a preclinical model of epilepsy. |
| 2015-09-23 | Addex Pharma S.A. | Results Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that ADX71149, a metabotropic glutamate receptor type 2 (mGluR2) positive allosteric modulator (PAM), demonstrated synergistic efficacy with levetiracetam (a globally commercialized antiepileptic drug) in preclinical models of epilepsy. |
| 2014-02-07 | Addex Pharma S.A. | Results Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms addextherapeutics.com ↗
Based on a preliminary analysis of the primary efficacy end point, the 6-Item Hamilton Anxiety Subscale, (HAM-A6), ADX71149 did not meet the criterion for efficacy signal detection versus placebo. |
| 2012-11-05 | Addex Pharma S.A. | Results Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients addextherapeutics.com ↗ |
| 2010-09-02 | Addex Pharma S.A. | Results Addex Drug Candidate Effective in Alzheimer’s Disease Model addextherapeutics.com ↗
In the preclinical study, the mGluR2 NAM dose-dependently reversed memory deficit exhibited after beta-amyloid protein administration. |
All press releases naming this drug 21 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ 40411813 | “The purpose of this study is to explore the safety, tolerability, and potential clinical efficacy of JNJ 40411813 in schizophrenic patients.” NCT01323205 ↗ |
| Known as | ADX71149 | “Metabotropic glutamate receptor-2 positive allosteric modulator, JNJ-40411813 (ADX71149), was characterised for clinical effects in healthy volunteers in two phase-1 studies.” PMID 25735992 ↗ Mar 2015 |
| Action | Activate | “Metabotropic glutamate receptor 2 positive allosteric modulator” CHEMBL3337527 ↗1“positive allosteric modulator of mGluR2” PMID 25735992 ↗ Mar 2015 |
| Modality | Small molecule | — CHEMBL3337527 ↗ |
| Route | Oral | “Patients will take JNJ-40411813 and placebo capsules orally (by mouth) twice daily (bid) with a meal.” NCT01323205 ↗ |
| Target | GRM2 | “Metabotropic glutamate receptor 2 positive allosteric modulator” CHEMBL3337527 ↗ |